Clinical trial · Observational
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer
Far Eastern Memorial Hospital
NCT03695809CI-TRIAL-00065121unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess the G9a expression in vulvar cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Vulvar Cancer, G9a Protein | Malignant Vulvar Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| G9a protein | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Correlation between clinical outcome of vulvar cancer and G9a
- timeFrame
- 5 years
- description
- The association of G9a protein and clinical outcome (such as overall survival and progression-free survival) of patients with vulvar cancer
Secondary outcomes (1)
- measure
- Correlation between histopathologic features of vulvar cancer and G9a
- timeFrame
- 1 year
- description
- Correlation between histopathologic features (such as tumor grade, lymphovascular space invasion, lymph node metastasis and tumor size) of vulvar cancer and G9a
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * All female patients with vulvar cancer or vulvar intraepithelial neoplasm II /III who underwent surgery at Far Eastern Memorial Hospital from January 2003 were included. Exclusion Criteria: * N/A
References
Publications (0)
Data not yet available
No reference posted for this study.